

## Company In-Depth

19 February 2007 | 13 pages

# Mahindra & Mahindra (MAHM.BO)

## Maintain Buy: Raising Target Price

 Rating change   
 Target price change   
 Estimate change 

- Raising estimates, target price** — Raising target price to Rs1,032 (from Rs702) as we are raising cash earnings by 9-10% over FY07E/09E, and factoring in higher subsidiary valuations (run up in Tech Mahindra's share price). We value M&M on a sum-of-parts methodology, core value at Rs543/sh (11x FY08E cash EPS) and Rs489/sh (for subsidiaries and the auto component initiatives).
- Continued dominance in tractor market** — M&M has consolidated on its dominant presence in the domestic tractor market – current market share is around 30%, through greater focus on the sub 30hp segment (traditionally a weaker segment for M&M). We contend that M&M might further consolidate its leading position in the tractor industry through inorganic initiatives.
- Recouping market share in core UV business** — M&M has recently recouped nearly 9% market share in the UV segment (market share currently at 53%), due to performance of the Maxx pick-up variant it launched in Sept 06. We expect M&M's core auto volumes to post a 10% CAGR over FY07E-09E. Operating leverage benefits should continue, mitigating material cost pressures.
- New initiatives gain momentum** — M&M's Renault JV will launch the *Logan* in 1QFY08; JV with Navistar should be operational in mid CY08E. Both JVs have enhanced scope and scale of operations. M&M's auto components initiative (Systech) is ahead of its schedule of attaining its USD1bn revenue target (given recent acquisitions in Germany, with more on the anvil).

<b>Buy/Low Risk</b>	<b>1L</b>
Price (15 Feb 07)	Rs901.60
Target price	Rs1,032.00
	<i>from Rs702.00</i>
Expected share price return	14.5%
Expected dividend yield	1.4%
<b>Expected total return</b>	<b>15.9%</b>
Market Cap	Rs220,422M
	US\$5,019M

### Price Performance (RIC: MAHM.BO, BB: MM IN)



See Appendix A-1 for Analyst Certification and important disclosures.

Figure 1. M&M – Statistical Abstract

Year to	Net Profit	Core EPS	EPS Growth	P/E	Price /CF	EV / EBITDA	ROE	ROCE	DPS	Div. Yield
31-Mar	(Rs mills)	(Rs)	(%)	(x)	(x)	(x)	(%)	(%)	(Rs)	(%)
2005	5,023	36.9	62.5	24.5	17.1	24.2	27.1	26.2	13.0	1.4
2006	6,688	24.3	-34.2	37.2	28.1	20.1	34.8	26.0	9.5	1.1
2007E	9,137	32.6	34.3	27.7	22.2	15.7	31.6	27.2	12.5	1.4
2008E	10,903	40.0	22.7	22.6	18.3	13.0	27.0	26.5	14.4	1.6
2009E	12,200	44.5	11.3	20.3	15.9	11.2	25.7	27.0	16.4	1.8

Source: Company, Citigroup Investment Research estimates

Jamshed Dadabhoy<sup>1</sup>

+91-22-6631-9883

jamshed.dadabhoy@citigroup.com

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD.

<sup>1</sup>Citigroup Global Market India Private Limited

Fiscal year end 31-Mar	2005	2006	2007E	2008E	2009E
<b>Valuation Ratios</b>					
P/E adjusted (x)	20.8	34.4	25.2	21.1	18.9
EV/EBITDA adjusted (x)	33.3	28.5	20.5	17.4	14.9
P/BV (x)	5.2	7.2	6.0	5.1	4.3
Dividend yield (%)	1.4	1.1	1.4	1.7	1.9
<b>Per Share Data (Rs)</b>					
EPS adjusted	43.30	26.18	35.76	42.67	47.75
EPS reported	44.19	33.55	40.90	42.67	47.75
BVPS	173.46	124.63	150.90	178.14	208.39
DPS	13.00	10.00	13.00	15.00	17.00
<b>Profit &amp; Loss (RsM)</b>					
Net sales	65,110	79,772	94,843	108,276	123,086
Operating expenses	-60,539	-74,431	-86,988	-99,190	-112,997
<b>EBIT</b>	<b>4,571</b>	<b>5,341</b>	<b>7,855</b>	<b>9,086</b>	<b>10,088</b>
Net interest expense	-302	-270	-300	-350	-580
Non-operating/exceptionals	2,733	3,570	4,547	5,899	7,091
<b>Pre-tax profit</b>	<b>7,001</b>	<b>8,641</b>	<b>12,102</b>	<b>14,635</b>	<b>16,599</b>
Tax	-2,015	-2,424	-3,391	-3,732	-4,399
Extraord./Min.Int./Pref.div.	141	2,354	1,739	0	0
<b>Reported net income</b>	<b>5,127</b>	<b>8,571</b>	<b>10,450</b>	<b>10,903</b>	<b>12,200</b>
Adjusted earnings	5,023	6,688	9,137	10,903	12,200
Adjusted EBITDA	6,411	7,341	9,890	11,484	13,187
<b>Growth Rates (%)</b>					
Sales	33.6	22.5	18.9	14.2	13.7
EBIT adjusted	56.7	16.9	47.1	15.7	11.0
EBITDA adjusted	40.3	14.5	34.7	16.1	14.8
EPS adjusted	56.5	-39.5	36.6	19.3	11.9
<b>Cash Flow (RsM)</b>					
<b>Operating cash flow</b>	<b>5,148</b>	<b>9,882</b>	<b>10,393</b>	<b>12,456</b>	<b>14,461</b>
Depreciation/amortization	1,841	2,000	2,035	2,398	3,098
Net working capital	-1,819	-689	-2,092	-845	-837
<b>Investing cash flow</b>	<b>-3,375</b>	<b>-4,974</b>	<b>-2,969</b>	<b>-12,000</b>	<b>-12,500</b>
Capital expenditure	-2,733	-2,543	-4,708	-7,000	-7,000
Acquisitions/disposals	-642	-2,431	1,739	-5,000	-5,500
<b>Financing cash flow</b>	<b>2,110</b>	<b>-852</b>	<b>5,722</b>	<b>-3,601</b>	<b>-4,162</b>
Borrowings	3,228	-1,692	7,423	-150	-150
Dividends paid	-1,720	-2,782	-3,644	-4,204	-4,765
<b>Change in cash</b>	<b>3,883</b>	<b>4,056</b>	<b>13,146</b>	<b>-3,145</b>	<b>-2,200</b>
<b>Balance Sheet (RsM)</b>					
<b>Total assets</b>	<b>50,064</b>	<b>60,030</b>	<b>79,169</b>	<b>88,966</b>	<b>99,656</b>
Cash & cash equivalent	6,240	7,303	19,085	16,047	13,854
Accounts receivable	5,115	6,380	7,991	9,114	10,360
Net fixed assets	14,749	15,544	18,217	22,820	26,721
<b>Total liabilities</b>	<b>29,942</b>	<b>30,941</b>	<b>42,069</b>	<b>45,167</b>	<b>48,421</b>
Accounts payable	10,949	13,707	16,151	18,389	20,882
Total Debt	10,526	8,834	16,257	16,107	15,957
<b>Shareholders' funds</b>	<b>20,123</b>	<b>29,089</b>	<b>37,100</b>	<b>43,799</b>	<b>51,234</b>
<b>Profitability/Solvency Ratios (%)</b>					
EBITDA margin adjusted	9.8	9.2	10.4	10.6	10.7
ROE adjusted	26.5	27.2	27.6	27.0	25.7
ROIC adjusted	18.2	19.6	25.9	25.1	22.2
Net debt to equity	21.3	5.3	-7.6	0.1	4.1
Total debt to capital	34.3	23.3	30.5	26.9	23.7

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



## Raising earnings for FY07E-09E

### Citigroup Investment Research Ratings Distribution

Data current as of 31 December 2006	Buy	Hold	Sell
<b>Citigroup Investment Research Global Fundamental Coverage (3106)</b>	<b>43%</b>	<b>41%</b>	<b>15%</b>
% of companies in each rating category that are investment banking clients	45%	41%	34%
India -- Asia Pacific (118)	58%	14%	28%
% of companies in each rating category that are investment banking clients	48%	50%	39%
<b>EBITDA (Rs m)</b>			
Old	9,283	10,909	12,621
New	9,890	11,484	13,187
% Change	6.5	5.3	4.5
<b>EBITDA Margin (%)</b>			
Old	10.1	10.4	10.7
New	10.4	10.6	10.7
<b>PAT (Recurring, does not include gains on stake sales, etc) (Rs m)</b>			
Old	7,504	8,880	10,453
New	9,137	10,903	12,200
% Change	21.8	22.8	16.7
<b>EPS (FD) (Rs)</b>			
Old	29.9	35.4	41.7
New	35.8	42.7	47.8
% Change	19.5	20.5	14.5
<b>Core EPS (fully diluted, excludes dividends from subsidiaries) (Rs)</b>			
Old	28.2	33.3	39.2
New	32.6	40.0	44.5
% Change	15.6	19.9	13.6
<b>CEPS (fully diluted, excludes dividends from subsidiaries) (Rs)</b>			
Old	37.3	45.0	52.0
New	40.5	49.4	56.6
% Change	8.6	9.7	8.9

Source: Citigroup Investment Research estimates


## Core businesses – Revival in UV segment is encouraging; we expect tractors to slow in FY08

Figure 2. Mahindra & Mahindra – Volume Assumptions

	FY06	FY07E	FY08E	FY09E
<b>Total UVs</b>	114,694	127,368	139,740	152,440
% change YoY	3.2	11.1	9.7	9.1
<b>3 wheelers</b>	22,419	35,000	39,200	43,904
% change YoY	(2.3)	56.1	12.0	12.0
<b>LCVs</b>	4,944			
% change YoY	(37.3)			
<b>Total Domestic Autos</b>	142,057	162,368	178,940	196,344
% change YoY	0.1	14.3	10.2	9.7
<b>Exports (Autos)</b>	5,534	8,578	12,009	15,611
% change YoY	81.7	55	40	30
<b>Total Autos</b>	<b>147,591</b>	<b>170,946</b>	<b>190,949</b>	<b>211,955</b>
% change YoY	1.8	15.8	11.7	11.0
<b>Tractors</b>				
Domestic sales	78,048	94,438	105,771	114,232
% change YoY	30.1	21.0	12.0	8.0
Export sales	6,981	8,098	9,313	11,175
% change YoY	29.6	16.0	15.0	20.0
<b>Total Tractors</b>	<b>85,029</b>	<b>102,536</b>	<b>115,083</b>	<b>125,407</b>
% change YoY	30.0	20.6	12.2	9.0

Source: Company, Citigroup Investment Research estimates

Figure 3. M&M's UV Market Share (%)



Source: SIAM

Over the past few months, M&M has recouped nearly 900bps market share in the UV segment (market share currently at 53%), due to the performance of the Maxx pick-up variant that it launched in Sept 06. Consequently, non-*Scorpio* UV sales are up 8% YTD, while *Scorpio* sales are up 17% YTD. Factoring the gains in market share, which we expect to be sustained over the near term, we have raised our UV volume forecasts for both FY08 and FY09 by 3% and 2%, respectively. M&M's new platform development (Ingenio) remains on schedule, with models expected to be launched in CY08E. We expect the Ingenio platform to be positioned between the Bolero and the Scorpio (in terms of price points). Thus, by 2HFY09E / FY10E, M&M should have three primary UV platforms, which should enable the company to undertake cost-cutting initiatives, especially on components, aggregates and assemblies, and also result in platform rationalization over the longer term.

We forecast c.11% volume growth for tractors over FY08-09. After robust growth of 32%, 30% and 21% over FY05-FY07E, we expect growth rates to taper off in FY08, but believe that M&M is well positioned to maintain or improve upon its domestic market share, given its exposure to southern and western India. Moreover, support from MMFSL (its tractor/UV finance arm) should also enable Mahindra to offset some of the slowdown that we expect over the next fiscal. In addition, new product launches (like that of the 'Shaan', which finds application in haulage and farming activities), might result in M&M's tractor growth exceeding our estimates.

## Joint ventures – scale of strategic initiatives enhanced

Over the past two years, M&M has entered into two JVs, with ITEC (International Truck and Engine Corporation (for MHCVs) and with Renault (for the manufacture of the Logan). M&M will hold 51% equity in both JVs.

Subsequently, M&M has enhanced the scale of operations with both Renault and ITEC

**Figure 4. JVs – Original Agreement**

	Partner	Total outlay (Rs bn)	M&M's equity investment (Rs bn)	Product details	Expected launch
Mahindra International Ltd	ITEC	4.0	1.0	MHCVs from 9 - 45MT	CY07
Mahindra Renault Private Ltd	Renault	6.8	1.7	Renault Logan	1QFY08

Source: Company Reports

**Figure 5. Joint Ventures - Enhanced Scope of Operations**

Partner	Capacity - by end FY12 / 13	Investment CIR (USD bn)	Comments
ITEC	250,000	0.5	Production to commence from end FY09E, first phase capacity of 250k units, could be further enhanced; gives M&M new opportunities in the domestic and export car markets. M&M might also get access to powertrain technology.
Renault	500,000	1	Initial installed capacity of 300,000 units, to be operationalised by end FY09E. We contend Renault will export at least 200,000 cars by CY10. Enables M&M to carve out a presence in the CV segment

Source: Company Reports, Citigroup Investment Research estimates

## Q&As on the initiatives with ITEC and Renault

### Do we incorporate value of these projects in M&M?

No. We incorporate the earnings streams from both JVs into M&M's core earnings. We believe that valuing these investments separately would result in double counting. We reckon that greater value will emerge once more clarity arises on: a) capex details; b) timelines; and c) details on the models to be launched, markets that will be addressed, etc. We contend that execution risk is also embedded in such large scale projects, which would not get adequately captured, if we were to value the businesses on a DCF-based methodology.

### What is the expected capex for both these projects?

No details have been disclosed – but we estimate that for the car project, the total capex will be around US\$1bn (Maruti will incur capex of around US\$500m for a 300,000 unit plant). We estimate that M&M/Renault will incur around US\$1bn for a plant with a capacity of 500,000 units. Our estimates appear slightly skewed toward the upper end, but we believe that if there are multiple platforms, etc, then overall capex will be around US\$1bn. Our estimate for the CV plant is US\$0.5bn.

### What is M&M's contribution to these initiatives?

We believe that M&M will invest around US\$750m over the next five years in these ventures, of which the equity contribution will be about US\$375m. We

factor M&M's equity contribution at US\$233m over FY08E-09E (with the residual being invested in FY10E-12E), although if the pace of the projects is ahead of schedule, it could exceed our forecasts. M&M's balance sheet is fairly healthy at this juncture (est. debt/equity of 0.4x end FY07E), and thus there is scope to further leverage (either on M&M's balance sheet, or the consolidated balance sheet).


**What are the near-term benefits for M&M from these initiatives?**

None - M&M will benefit from access to technology and entry into the CV/passenger car industries, which will likely result in a more diversified revenue profile, but these will come through in a meaningful manner only from FY09E/FY10E. The only benefit for M&M (which might start coming through from early FY09E) will be an increase in its bargaining power with vendors (for components and parts), as it leverages off the economies of sourcing that will start coming through.

**Subsidiaries – Summing up the parts**

M&M's (parent entity)<sup>1</sup> profits accounted for around 61% of overall FY06 Mahindra group profits (vs. 74% in FY05). Given the significant contribution from the group companies, and the recent IPO of Tech Mahindra, we believe there is a compelling argument to value some of Mahindra's key subsidiaries (both listed and unlisted).

**Figure 6. Consolidated group Profits (FY06, %)**



Source: Company Reports

**Figure 7. M&M – Valuation of Key Listed Subsidiaries**

Company	M&M Holding	Value (Rs / share of MM)
Tech Mahindra	46.4%	297
MMFSL	67.7%	44.4
Mahindra Gesco	46.1%	36.4
<b>Total</b>		<b>377.8</b>

Source: Bloomberg, Company

Note: Shares are valued at 15% discount to market prices. Market prices are simple average of the preceding two weeks

**Auto component initiatives – Too large to be ignored**

M&M is targeting a near doubling of revenues in its auto component division's (Systech) revenues – to US\$1bn by FY10, from c\$600m currently. The division's current structure is shown in Figure 9.

<sup>1</sup> Computed on total profits (including exceptional items), but excluding minority interest

**Figure 8. Systech (formerly Mahindra Systems and Automotive Technologies Sector)**

1 ACBU - Auto Component Business Unit		
Name	Description	
MUSCO (Mahindra Ugine Steel)	Alloy and Precision Steel	
Siro Plast	Engineering Polymer Composites	
Stokes Group	Forgings	
Amforge's Chakan Unit	Forgings	
Pranay Sheet Metal Stampings Ltd	Sheet Metal Components	
Sar Auto Transmissions	Gear Unit	
Jeco	Forgings	
Schoneweiss	Forgings	
DGP Hinoday	Castings	
2 SSBU - Strategic Sourcing Business Unit		
Contract sourcing for global OEMs		
3 Engineering Services		
Name	Description	
Mahindra Engineering Services	Design, Tools, Prototyping, Integration, Packaging, Testing	
Plexion Technologies	Design for automotive and aerospace	
Mahindra Engineering Design and Development Company	Engineering services for the auto sector	

Source: Company Reports

Management indicated recently that the revenue target of US\$1bn might be achieved in 2009 (vs. target of 2010). Given the sedate growth in the European market (to which the larger businesses like Jeco, Schoneweiss, etc.) cater to, we contend that the US\$1bn revenue target will likely be achieved through inorganic, rather than organic initiatives, which implies that there are more acquisitions - on the anvil. Systech appears to be following the strategy of companies such as Bharat Forge and Amtek Auto – acquiring companies in Europe to acquire customer share, and to scale up the technology curve. The recent acquisitions of Stokes, Jeco and Schoneweiss should enable M&M to effectively address the car and truck markets in Europe.

**Figure 9. Primary Companies in the Systech Fold**

Company	Mahindra's Stake (%)
MUSCO	51%
Mahindra Forgings	47%
Mahindra Composites	45%
Stokes	99%
Jeco	68%
Schoneweiss	90%
MEDDCL	100%
Plexion	99%
Mahindra SAR Transmission	51%
DGP Hinoday	67%


Source: Citigroup Investment Research

We believe that over the longer term, the auto component business will also cater to the Mahindra–Renault JV and the Mahindra–Navistar JV, which will provide it a substantial captive market in India, in addition to the outsourcing opportunity available. As per plan, M&M and its JV partners Renault and International Trucks are targeting to manufacture around 300,000 cars and 250,000 CVs from 2010. We estimate that even if 150,000 cars and 100,000 trucks are manufactured and exported (or sold in the domestic market) by FY10, it will provide an opportunity for forgings and castings of US\$300m-400m p.a. (which will increase as export volumes increase).

We are thus optimistic about the long-term growth prospects of Systech, as we believe that outsourcing to low-cost countries like India is a structural shift that will endure over the long term. That said, our concerns with Systech and its related businesses, at this juncture, emanate from: a) integration issues of the various businesses; and b) lack of clarity on the balance sheets of the acquired companies. Per management, recent acquisitions (such as Jeco and Schoneweiss) have been undertaken at valuations of 5-6x EBITDA, but as yet we have limited clarity on the overall capex for all the businesses, and also the capital outlay for these businesses, going forward.


We value Systech at 12x FY08E P/E (for M&M's share), which implies a value of Rs57/share of M&M; or an equity value of US\$323m. At this juncture, we think 12x is a fair multiple (nearly 15% discount to M&M's FY08E EPS multiple). Going forward, a re-rating of the business might occur as clarity emerges on issues like integration, growth strategy, etc.

Figure 10. Systech – Revenue Growth – FY06-09E



Source: Company, Citigroup Investment Research estimates

Figure 11. Systech – Margin Trends – FY06-09E



Source: Company, Citigroup Investment Research estimates

## Mahindra & Mahindra Company description

Mahindra and Mahindra manufactures utility vehicles, light commercial vehicles and tractors. It has recently entered the 3-wheeler segment. M&M is the market leader in both the utility vehicle and tractor segments.

## Valuation

Figure 12. M&M – Valuation Summary

Target Price Computation	Valuation Metric	Rs / Share
Core business	11x FY08E Cash Earnings Per Share	543
Listed subsidiaries (Tech Mahindra, MMFSL, Gesco)	15% discount to market price	402
Mahindra Holidays and Resorts	18x FY06 PAT (at c40% discount to listed comparables like Indian Hotels, East India)	15
Systech (Auto component initiatives)	12x FY08E P/E	57
Other subsidiaries (at book value)	1x Book value	15
<b>Total</b>		<b>1,032</b>


Source: Citigroup Investment Research estimates

Our target price of Rs1032 is based on a sum-of-parts methodology. We value M&M's core business at Rs543 (formerly Rs495 – revised on the back of earnings upgrades – multiple remains unchanged at 11x FY08E core CEPS). We also incorporate value for M&M's listed subsidiaries (Rs402 / share), its auto



component business (Rs57 /share) and M&M's investments in other subsidiaries (including Mahindra Holidays at Rs30 /share). Our core multiple of 11x, is supported by an 18% CAGR in core cash earnings (excluding dividends from group companies) for M&M over FY07E-09E. We value the key subsidiaries / associates / auto component initiatives at Rs459/share. At our core target price (of Rs543) the stock would trade at around 13.6x FY08E core EPS (excluding dividends from subsidiaries) and should be supported by 16% CAGR in earnings over FY07E-09E.

Figure 13. M&M – Share Price Vs. Sensex



Source: Datastream

Figure 14. M&M - Absolute and Relative Performance

	3M	6M	12M
Absolute	3.4	41.9	45.6
Relative	-1.7	12.7	5.1

Source: Datastream

We have chosen to use P/CEPS as our primary valuation metric to ensure proper comparison with historical trading bands — the company is undertaking a significant product development and capital expenditure program, and also undertook a restructuring of the balance sheet in FY02.

We believe valuations will also be supported by: a) management’s continued efforts to unleash value from investments in group concerns (we believe that the listing of the group’s hotel / resorts venture is next on the anvil); and b) new initiatives announced in the passenger cars, commercial vehicles and auto components segments, which should fructify over the next 2-3 years.

### Investment thesis

We rate M&M Buy/Low Risk (1L) with a target price of Rs1,032. Tractor sales are benefiting from relatively low penetration levels and the government’s emphasis on increasing credit to the agriculture sector. Apart from dominance of the lower end of the market, wherein competition has been limited, M&M’s utility vehicle business is also benefiting from product initiatives, particularly the launch of the Scorpio and Bolero models and variants of these, which have enabled M&M to tap into the urban markets for passenger vehicles. Moreover, we also recognize management’s efforts to retain market share within segments like 3 wheelers, given the stiff competition in this segment.

We remain enthused by management’s efforts to de-risk from the local market by pursuing sales in select international markets. The target is to raise international sales from around 10% at present to 20% over the next three years. Their efforts have met with substantial success particularly in the tractor segment, wherein they are currently ranked No. 4 (in terms of unit sales) globally.

The substantial value of the company’s real estate and investment holdings (particularly in the information technology business through Tech Mahindra and in the financial services business through M&M Financial Services) should provide downside support (especially with increasing dividends from key subsidiaries). Given recent initiatives to unlock value in subsidiaries – MMFSL and Tech Mahindra being the primary examples – we incorporate the value of key subsidiaries within our sum-of-parts valuation.

### Risk

We rate M&M Low Risk, in line with our quantitative model that tracks 260-day volatility. Key Risk factors to our investment thesis:

- 1) Substantial rise in interest rates that could curb demand for farm equipment and utility vehicles;

- 2) Given M&M's strong dependence on the rural economy (a substantial part of the demand for their products emanates herein), any weak trend in the prices of agricultural commodities could also impact demand and sales;
- 3) Escalating competition within the UV segment, which might lead to increase in discounts and result in margin pressure;
- 4) Input costs are volatile and linked to global commodity prices for metals, plastics, etc. and could impact margins and in turn, profitability; and
- 5) Any substantial capital outlay for inorganic initiatives.

## Appendix A-1


### Analyst Certification

I, Jamshed Dadabhoy, research analyst and the author of this report, hereby certify that all of the views expressed in this research report accurately reflect my personal views about any and all of the subject issuer(s) or securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### IMPORTANT DISCLOSURES

#### Mahindra and Mahindra Ltd (MAHM.BO) Ratings and Target Price History - Fundamental Research

Analyst: Jamshed Dadabhoy (covered since March 1 2006)



Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Mahindra and Mahindra Ltd. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Mahindra and Mahindra Ltd.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Mahindra and Mahindra Ltd.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Mahindra and Mahindra Ltd in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Mahindra and Mahindra Ltd.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Mahindra and Mahindra Ltd.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Mahindra and Mahindra Ltd.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at [www.citigroupgeo.com](http://www.citigroupgeo.com). Private Client Division clients should refer to [www.smithbarney.com/research](http://www.smithbarney.com/research). Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

#### Citigroup Investment Research Ratings Distribution

Data current as of 31 December 2006

	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (3106)	43%	41%	15%
% of companies in each rating category that are investment banking clients	45%	41%	34%
India -- Asia Pacific (118)	58%	14%	28%
% of companies in each rating category that are investment banking clients	48%	50%	39%

#### Guide to Fundamental Research Investment Ratings:

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

**Risk ratings**, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

**Investment ratings** are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks,

10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

---

## OTHER DISCLOSURES

---

The subject company's share price set out on the front page of this Product is quoted as at 15 February 2007 04:00 PM on the issuer's primary market.

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of equity securities of Mahindra and Mahindra Ltd.

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of fixed income securities of Mahindra and Mahindra Ltd.

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of Mahindra and Mahindra Ltd.

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of Mahindra and Mahindra Ltd.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

This Product has been modified by the author following a discussion with one or more of the named companies.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities

Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 Lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartościowych i Giełd. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at [www.citigroupgeo.com](http://www.citigroupgeo.com). Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

---

© 2007 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

---

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST

---